Sisram Medical Ltd will hold its annual general meeting on 24 June 2026 at 2:00 p.m. in Hong Kong. Shareholders will vote on multiple resolutions that concentrate on capital management, board continuity and audit matters.

Key proposals 1. Capital mandates • Share Buy-back: Directors request authority to repurchase up to 46.83 million shares, equal to 10 % of the company’s 468.34 million issued shares (excluding treasury shares). • Share Issuance: A separate mandate would allow issuance of up to 93.67 million new shares (20 % of issued capital). An additional resolution would enlarge this limit by the number of shares actually repurchased.

2. Board composition • Executive directors Lior Moshe Dayan (Chairman) and Jiahong Li (Co-CEO & CFO) plus non-executive directors Yi Liu and Caroline Xiaokui Jin stand for re-election. • Independent non-executive directors Heung Sang Addy Fong and Chi Fung Leo Chan are nominated for a further three-year term as external directors under Israeli law.

3. Auditor • Re-appointment of Ernst & Young as external auditor through FY 2026 with an estimated audit fee between US$0.49 million and US$0.54 million.

Additional information • Record date for voting: 17 June 2026; proxy forms must reach Computershare Hong Kong by 2:00 p.m. on 22 June 2026. • Fosun International Holdings, via subsidiaries, controls 71.42 % of Sisram Medical’s shares. The company notes that a full utilisation of the buy-back mandate would not trigger any mandatory offer under Hong Kong’s Takeovers Code.

All agenda items are ordinary resolutions requiring shareholder approval by poll. No refreshments or corporate gifts will be provided at the meeting.